Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.38 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 6/20 | 0.33 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.32 |
| ▸ | WDR5 | P61964 | 2/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21884640 | 0.93 | NISCH (0.35) | NISCHADRA1DSLC6A3WDR5ADRA2A | |
| SCHEMBL21884365 | 0.92 | NISCH (0.38) | NISCHADRA1DSLC6A3WDR5ADRA2A | |
| SCHEMBL21884373 | 0.90 | NISCH (0.38) | NISCHADRA1DSLC6A3ADRA2AADRA2B | |
| SCHEMBL21884363 | 0.89 | NISCH (0.41) | NISCHADRA1DSLC6A3USP30WDR5 | |
| SCHEMBL21884368 | 0.89 | WDR5 (0.35) | NISCHADRA1DSLC6A3WDR5ADRA2A | |
| SCHEMBL21884636 | 0.89 | NISCH (0.34) | NISCHCD274LRRK2ADRA1DSLC6A3 | |
| SCHEMBL23875072 | 0.88 | NISCH (0.38) | NISCHPDCD1CD274ADRA1DSLC6A3 | |
| SCHEMBL21884493 | 0.88 | WDR5 (0.34) | NISCHPDCD1CD274ADRA1DSLC6A3 | |
| SCHEMBL24066340 | 0.86 | NISCH (0.35) | NISCHCD274LRRK2ADRA1DSLC6A3 | |
| SCHEMBL21884391 | 0.85 | NISCH (0.37) | NISCHADRA1DSLC6A3ADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210371403-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | JNANA THERAPEUTICS INC. | 2021-12-02 | — | — | US | disclosed |
| US-20210299070-A1 | METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY | JNANA THERAPEUTICS INC. | 2021-09-30 | — | — | US | disclosed |
| WO-2020061473-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | JNANA THERAPEUTICS, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210299070-A1 | METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY | SLC19A1, SLC1A5, SLC1A2 | NISCH 1713/4885PDCD1 4818/4885CD274 4884/4885 |
| US-20210371403-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | SNRPE, G3BP1, G3BP2 | NISCH 4403/4885PDCD1 3365/4885CD274 4662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.